Oxygen-guided Supervised Exercise Therapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Supervised exercise therapy.
- Who it may be relevant to
- Registry conditions: Peripheral Artery Disease. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Oxygen-guided Supervised Exercise Therapy in Peripheral Artery Disease
Overview
Peripheral artery disease (PAD) is a cardiovascular disease manifesting from systemic atherosclerosis, which blocks the leg arteries and results in insufficient blood flow to the lower extremities. Limb ischemia from PAD is the most common disorder treated within the vascular surgery service at the Omaha Veterans' Affairs Medical Center. PAD also accounts for one-third of the operations performed in the VA Medical Centers nationwide. This project aims to establish the feasibility and acceptability of a muscle oxygen-guided supervised exercise program for patients with PAD. The investigators will determine the potential benefits of using this intervention over standard supervised exercise therapy. This modified intervention may enable patients to increase overall physical activity without the negative impacts on muscle structure and function. Increasing physical activity will decrease cardiovascular morbidity and mortality. If proven beneficial, the findings will lead to an improved exercise program that directly benefits veterans nationwide.
Detailed description
The long-term goal of this research is to improve mobility, functional independence, and quality of life in patients with peripheral artery disease (PAD) by developing conservative interventions. PAD is a manifestation of atherosclerosis, which produces blockages in the leg arteries, and results in insufficient blood flow to the legs. PAD results in significant gait deficits and an overall sedentary lifestyle. The investigators' prior work showed that the biochemical (oxidative stress and mitochondrial dysfunction) and histological (myofiber degeneration and fibrosis) characteristics of PAD muscles are altered compared to controls. These myopathic changes are due to cycles of ischemia and reperfusion, and they correlate to functional limitations (walking distance and calf muscle strength). Limb ischemia from PAD is the most common disorder treated within the vascular surgery service of the Omaha Veterans Affairs Medical Center. The most effective treatment for increasing the distances that patients with PAD can walk is supervised exercise therapy (SET). However, SET uses pain onset to guide exercise intensity and rest cycles. These repeated bouts of ischemia/reperfusion could cause further pathological damage to muscle myofibers and oxidative processes. Such adverse effects of ischemia may explain why not all patients improve with SET. Preventing cycles of ischemia-reperfusion during SET can improve walking performance without further muscle biochemistry damage in patients with PAD. The investigators propose using hemodynamic responses to modulate exercise intensity and prevent ischemia during SET. Muscle oxygen-guided supervised exercise therapy (M-SET) can prevent ischemia onset and thus preserve muscle mass and function during exercise therapy in patients with PAD. The aims are:
Aim 1: To determine the exercise outcomes of an M-SET versus a standard SET session in patients with PAD. Aim 2: To determine the acute effect of M-SET versus standard SET on oxidative stress and inflammation in patients with PAD. Aim 3: To determine the effect of 12 weeks of M-SET versus standard SET on exercise outcomes, muscle biochemistry, and subject-reported preference in patients with PAD.
The investigators will measure exercise outcomes during one session each of M-SET (using StO2 on the calf to modulate exercise) and SET, in 12 patients with PAD using a cross-over design. Exercise outcomes will be assessed by the total distance patients walked during the session, metabolic cost, metabolic equivalents of the task, physical activity enjoyment, and rate of perceived exertion. In Aim 2, oxidative stress will be measured using peripheral blood mononuclear cells before and after each exercise session (SET and M-SET) in all patients. During the standard SET session, subjects will walk until claudication pain becomes severe and the participant needs to stop. Then subjects will rest until claudication pain subsides. Afterward, subjects will walk again, repeating the cycle for up to 50 minutes. M-SET will use an StO2 threshold that is 15% lower level than baseline StO2 levels. Subjects will stop walking once they reach the threshold and rest until StO2 levels return to baseline. Then, subjects will begin walking again, repeating this cycle for 50 total minutes (including walking and rest). Patients from Aims 1 and 2 will be randomly assigned to either a 12-week M-SET or standard SET (6 per group) program. Training will be performed three times weekly as described above. Subjects will be evaluated before and after the intervention to capture initial and absolute walking distances and 7-day physical activity. Muscle biochemistry will be quantified using mitochondrial function, mitochondrial oxidative dynamics, and reactive oxygen species production before and after training. Results will support a full clinical trial and rehabilitation recommendations.
Interventions
- Behavioral Supervised exercise therapy
Subjects will be enrolled in a 12-week intervention program of either modified supervised exercise therapy or standard supervised exercise therapy. The program will be 3 sessions/week for 12 weeks. Each session will consist of 50 minutes plus 5 minutes warm up and cool down.
Primary outcome measures
- Distance walked [Time frame: Before and after 12 week exercise program]
- Energy expenditure [Time frame: Before and after 12 weeks after the exercise program]
- Reactive oxygen species [Time frame: Before exercise, immediately after exercise, 30 minutes after exercise, and 1 hour after exercise]
- Protein expression of ROS-related enzymes [Time frame: Before exercise, immediately after exercise, 30 minutes after exercise, and 1 hour after exercise]
- Markers of systemic inflammation [Time frame: Before exercise, immediately after exercise, 30 minutes after exercise, and 1 hour after exercise]
- Initial and absolute walking distances [Time frame: Before and after 12 week supervised exercise program]
- Comprehensive mitochondrial respiratory complex function [Time frame: Before and after 12 week supervised exercise program]
- Mitochondrial dynamics [Time frame: Before and after 12 week supervised exercise program]
- Mitochondrial reactive oxygen species production [Time frame: Before and after 12 week supervised exercise program]
Secondary outcome measures (8)
- Metabolic equivalents of task [Time frame: Immediate]
- Physical activity enjoyment scale [Time frame: Immediate]
- Rating of perceived exertion [Time frame: Immediate]
- Physical activity average steps/day [Time frame: Before and after 12 week supervised exercise program]
- Muscle strength [Time frame: Before and after 12 week supervised exercise program]
- Acceptability [Time frame: Before and after 12 week supervised exercise program]
- Maximum cadence/day [Time frame: Before and after 12 week supervised exercise program]
- Muscle endurance [Time frame: Before and after 12 weeks supervised exercise program.]
Eligibility criteria
Inclusion criteria
At entry into the study, all subjects must:
- Be able to give written, informed consent
- Have documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
- Demonstrate positive history of chronic claudication
- Have a stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks
Exclusion criteria
Any potential subjects will be excluded if they have:
- Rest pain or tissue loss due to PAD (Fontaine stage III and IV)
- Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma
- Walking capacity limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Basic science
Study locations
United States · 1 center
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha
Identifiers
NCT: NCT06003855 · E4632-P